Compare SKIL & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKIL | CSBR |
|---|---|---|
| Founded | 1998 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.1M | 90.0M |
| IPO Year | N/A | 1986 |
| Metric | SKIL | CSBR |
|---|---|---|
| Price | $7.90 | $6.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 310.7K | 22.1K |
| Earning Date | 12-10-2025 | 12-15-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.17 |
| Revenue | ★ $515,774,000.00 | $58,424,000.00 |
| Revenue This Year | N/A | $7.31 |
| Revenue Next Year | $0.75 | $12.01 |
| P/E Ratio | ★ N/A | $41.37 |
| Revenue Growth | N/A | ★ 9.06 |
| 52 Week Low | $4.65 | $5.59 |
| 52 Week High | $34.43 | $11.99 |
| Indicator | SKIL | CSBR |
|---|---|---|
| Relative Strength Index (RSI) | 44.69 | 56.99 |
| Support Level | $5.63 | $6.09 |
| Resistance Level | $8.85 | $7.52 |
| Average True Range (ATR) | 0.89 | 0.52 |
| MACD | 0.22 | 0.11 |
| Stochastic Oscillator | 73.81 | 52.77 |
Skillsoft Corp is a leader in corporate digital learning. The company's segments include Talent Development Solutions and Global Knowledge. Talent Development Solutions brings a foundation of products and customers. TDS enterprise-grade solution serves customers and employees world-wide. TDS Learner is a world-renowned consumer-scale and experiential learning platform that serves learners internationally. The Global Knowledge segment is centered around instructor-led training, or live learning, with face-to-face delivery by experienced trainers, both in-person and virtually.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.